DelveInsight Business Research LLP

Despite the approved drugs, current treatments often provide only limited and temporary relief, primarily addressing symptoms rather than the root causes, leaving patients with persistent discomfort and diminished quality of life. Companies such as Sanofi/Regeneron (DUPIXENT), GSK (Linerixibat), Galderma/Chugai Pharmaceutical Co., Ltd. (nemolizumab), Mirum Pharmaceuticals, Inc. (Volixibat), and others are advancing their therapies through various clinical trial stages, driving innovation in the chronic pruritus space and opening significant growth opportunities. Get a detailed assessment of how the launch of these therapies will change the market dynamics at: https://lnkd.in/dFC9NQfm #ChronicPruritus #ItchDisorders #Dermatology #SkinDiseases #PharmaInnovation #EmergingTherapies #ClinicalTrials #DrugDevelopment #Biotech #LifeSciences #PharmaNews #PipelineInsights #PatientCare #DermatologyResearch #HealthcareInnovation #DelveInsight

Artificial Intelligence is transforming the pharmaceutical landscape, making drug discovery faster, smarter, and more cost-effective. From target identification to clinical trials, AI is turning data into breakthroughs, helping researchers predict outcomes, design better molecules, and bring therapies to patients in record time. North America leads this AI-powered evolution, with growing adoption across Europe and Asia-Pacific. Industry pioneers like IBM, DeepMind, NVIDIA, Atomwise, Insilico Medicine, BenevolentAI, Exscientia, Valo Health, OWKIN, Verge Genomics, BioSymetrics (a Lunai Bioworks company), and more are redefining what’s possible in R&D through AI-driven molecular design, generative chemistry, and real-time analytics. As AI integrates with digital twins, predictive analytics, and cloud-based ecosystems, the next decade promises precision-driven, patient-centric drug discovery at scale. Read the full blog to explore how AI is reshaping the future of therapeutic innovation @ https://lnkd.in/dMV4JXSy #ArtificialIntelligence #AIDrugDiscovery #PharmaInnovation #DigitalTransformation #DrugDevelopment #GenerativeAI #LifeSciences #Biotech #PharmaR&D #PrecisionMedicine #HealthcareAI #PredictiveAnalytics #AIinPharma #PharmaTechnology #TherapeuticInnovation #MachineLearning #DeepLearning #CloudComputing #DigitalHealth #DelveInsight

The aging population is fueling the next wave of pharmaceutical growth, unlocking a projected $38 billion global opportunity in chronic and geriatric care therapies by 2034. DelveInsight’s latest executive whitepaper showcases how leading companies such as Pfizer, Johnson & Johnson, Roche, AstraZeneca, Sanofi, Eli Lilly and Company, Bristol Myers Squibb, Novartis, Amgen, Novo Nordisk, Daiichi Sankyo US, MSD, GSK, AbbVie, Boehringer Ingelheim, Teva Pharmaceuticals, Bayer, Takeda, Astellas Pharma, UCB, Otsuka Pharmaceutical Co., Ltd., SUN PHARMA, Regeneron, Biogen, Vertex Pharmaceuticals, Ipsen, Servier, and many more are redefining R&D, commercial strategies, and operational resilience to capture this unprecedented demographic shift. With the world’s population of adults 60+ set to double by 2050, the pharma market must reimagine commercial and operational strategy to serve evolving patient needs and unlock sustainable market impact. Discover actionable frameworks, commercial impact benchmarks, and exclusive case studies to help CXOs navigate fiscal sustainability, supply chain volatility, and the complexities of multimorbidity in aging populations. Download the whitepaper now to dive into data-driven insights and strategic mandates that span chronic care, biosimilars, digital therapeutics, and emerging market entry: https://lnkd.in/g83TnMCD #PharmaMarketResearch #AgeingPopulation #PharmaceuticalIndustry #HealthcareInnovation #ChronicCare #GeriatricCare #MarketIntelligence #PharmaLeaders #GlobalPharma #PharmaTrends #HealthcareStrategy #ExecutiveInsights #DigitalHealth #CommercialStrategy #Whitepaper #Biotech #MedTech #2025Trends

Big week for medtech breakthroughs! This week's #MedTechNews spotlights six game-changing industry updates: 1️⃣ OncoHost received the New York State Lab Permit for its PROphetNSCLC plasma proteomics test, enabling precision oncology to reach more patients across the state. 2️⃣ Onkos Surgical earned FDA 510k clearance for its ELEOS Proximal Tibia implant with NanoCept antibacterial technology, advancing orthopedic care with innovative contamination mitigation. 3️⃣ BD launched a simplified at-home HPV self-collection test, expanding global access to cervical cancer screening through advanced automation and user-friendly sample collection. 4️⃣ Oticon announced Zeal, a revolutionary hearing aid style in a discreet NXT in-the-ear category, powered by AI for exceptional sound quality and all-day connectivity. 5️⃣ Nyra Medical kicked off its first-in-human CARLEN system clinical trial for mitral valve repair, bringing new hope for patients with functional secondary mitral regurgitation. 6️⃣ Cordis unveiled 12-month results from its SELUTION SLR Drug-Eluting Balloon trials, guiding clinicians in coronary artery disease management and advancing minimally invasive cardiovascular therapy. These advances demonstrate medtech's pursuit of innovation in precision diagnostics, infection control, audiology, cardiology, and more. Read the full roundup and see what’s emerging next in medtech: https://lnkd.in/grPrY9s2 #Innovation #PrecisionMedicine #Oncology #Orthopedics #Cardiology #Diagnostics #HPVTesting #HearingAids #ClinicalTrials #Breakthroughs #Healthcare

The lights may have dimmed, but the memories still glow bright! This Diwali, the DelveInsight Business Research LLP family came together to celebrate with vibrant rangoli, traditional attire, and moments of joy that lit up our workspace. From laughter-filled activities to shared sweets and smiles, we embraced the spirit of togetherness and culture that makes our team truly special. Here’s a glimpse into how we celebrated the Festival of Lights, because at #DelveInsight, every celebration is a reflection of our people. #DelveInsight #DiwaliCelebration #FestivalOfLights #WorkplaceCulture #TeamSpirit #PostDiwaliVibes

DelveInsight Business Research LLP is looking for passionate professionals to join our Forecasting Team in the following roles: - Senior Associate - Lead Associate Experience: 2–4 years Work Mode: Hybrid Location: Gurugram Preferred: Immediate Joiners If you're ready to make an impact in life sciences and work with a dynamic, expert-driven team, we want to hear from you. 📩 Send your resume to hr@delveinsight.com. Learn more at https://lnkd.in/eyE77228 #Hiring #ForecastingJobs #LifeSciencesCareers #JoinOurTeam #DelveInsight

The Post Traumatic Stress Disorder (PTSD) market in the 7MM reached $1.8 billion in 2024 and is poised to grow at a robust CAGR of 12.2% (2025–2034), driven by evolving therapeutic options and promising late-stage pipeline candidates such as Brexpiprazole + Sertraline, BNC210, Lofexidine, and Psilocybin. Gain detailed insights into: - Epidemiological trends and burden by severity - Current treatment dynamics and unmet needs - Key clinical trials and upcoming therapies shaping the future landscape Pharma giants working in the PTSD market are Tonix Pharmaceuticals, Pop Test Oncology LLC, H. Lundbeck A/S, BIONOMICS LIMITED, Alto Neuroscience, Transcend Therapeutics, Jazz Pharmaceuticals, OTSUKA PHARMACEUTICALS (U.K.) LTD., and others. Delve deeper into the data, forecasts, and strategic intelligence shaping the PTSD market today! Download the full report now @ https://lnkd.in/g-bvGx8F #PostTraumaticStressDisorder #PTSD #DelveInsightReports #PharmaMarketInsights #MentalHealth #Biopharma #DrugDevelopment #MarketForecast #Epidemiology #ClinicalTrials #BNC210 #Brexpiprazole #Sertraline #Psilocybin #Lofexidine

From enzyme replacement therapy to groundbreaking gene and regenerative medicine approaches, the MPS I landscape is undergoing a major transformation. DelveInsight Business Research LLP’s latest report offers strategic insights into the evolving market dynamics, emerging therapies like OTL-203, JR-171, and RGX-111, and the future of disease-modifying treatments through 2034. Discover how innovation, awareness, and early diagnosis are reshaping outcomes for this ultra-rare lysosomal storage disorder. Pharma giants working in the market are JCR Pharmaceuticals, REGENXBIO, Talaris Therapeutics Inc., Orchard Therapeutics - U.S., Paradigm Biopharmaceuticals, Jupiter Neurosciences, Inc., and others. #DelveInsight explores how biotech and pharma leaders are driving breakthroughs to redefine patient outcomes and reshape the global MPS I market by 2034. Explore more @ https://lnkd.in/gZktyFJt #MPSI #RareDiseases #GeneTherapy #LysosomalStorageDisorders #DelveInsight #MarketInsights #DrugDevelopment #OrphanDiseases

Pharma News & Updates: FDA Approves Genentech’s GAZYVA for Lupus Nephritis Glaukos Corporation’ EPIOXA Wins FDA Approval for Keratoconus Treatment FDA Accepts Replimune’s RP1 BLA Resubmission for Advanced Melanoma Cogent’s Bezuclastinib Earns FDA Breakthrough Therapy for SM-AHN Amgen’s TEZSPIRE Gets FDA Nod for Chronic Rhinosinusitis with Nasal Polyps Get detailed insights @ https://lnkd.in/gVG4pRae #PharmaNews #FDAApproval #DrugDevelopment #BiotechUpdates #MedicalInnovation #PharmaInsights #ClinicalResearch #DrugDiscovery #DelveInsight #HealthcareUpdates #PharmaIndustry #BiotechNews #RegulatoryUpdates #TherapeuticAdvancements #PharmaMarket

Congratulations, Vikas Shrivastav, on completing your 1st work anniversary at DelveInsight Business Research LLP. Over the past year, Vikas has consistently shown professionalism, dedication, and a strong commitment to excellence, delivering high-quality reports, articles, and metadata. His enthusiasm for learning, growth, and collaboration has made a remarkable impact on our team. We’re excited to see you continue to grow and take on new challenges in the year ahead. Here’s to many more milestones together! #WorkAnniversary #TeamDelveInsight #EmployeeSpotlight #GrowthJourney #DelveInsight #Teamwork #ProfessionalGrowth